






## Norway

## **Recent and planned developments in pharmaceutical policies 2019**

## Special topic: patient-based reimbursement decisions



In order for a medicine to be reimbursed, a HTA (Health Technology Assessment) has to be performed to map the utility, resource use and severity of the disease. NOMA is responsible for the assessment.

Reimbursement can be granted only for long term treatment (>3 months), and can be applied for if:

- The accepted products available for general reimbursement do not provide sufficient effect
- The products available for general reimbursement cause unacceptable adverse reactions
- The patient differs from the patient group assessed for general reimbursement
- In most cases, all physicians with authorization in Norway can apply on behalf of his or her patient. For some products, it is required that the application is filled by a specialist in the field of the disease or a doctor from a relevant hospital department.
- The application has to be evaluated and the decision has to be made by HELFO (Norwegian Health Economics Administration) within 10 weeks.